Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6816)	7/25/2002 9:46:42 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Hi Peter, During the ICOS call tonight, Paul mentioned that Pafase Phase III enrollment is proceeding faster than plan. Yet they have the planned number of clinical sites. (100) Can any deduction be made re perceived efficacy of Pafase by the clinical staff? Usually I hear about slower enrollments than planned, not faster. Or is ICOS just being more aggressive in managing the trial and its incentives? OR is this just destined to be one of life's little mysteries? <g> Thanks, Ian